logo-loader
Advanced Oncotherapy PLC

Grant of options

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;font-weight:bold;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:70.9pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:106.3pt;text-align:justify;text-indent:-35.4pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:5.0cm;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:177.2pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}strong{font-family:"Times New Roman","serif";}em{font-family:"Times New Roman","serif";}p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}acronym{font-family:"Times New Roman","serif";} address{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-div:italic;}cite{font-family:"Times New Roman","serif";}code{font-family:Consolas;}dfn{font-family:"Times New Roman","serif";}samp{font-family:Consolas;}tt{font-family:Consolas;}var{font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .mx{size:595.3pt 841.9pt;margin:2.0cm 42.45pt 49.65pt 42.55pt;}div.mx{}p.os{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; text-align: center}span.oq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.ot{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.oo{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ou{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: center}span.om{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";}span.ok{font-family:"Calibri","sans-serif"} p.ov{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: center}span.oj{font-family:"Calibri","sans-serif";color:black}p.ow{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.ox{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align:justify}span.oi{font-family:"Calibri","sans-serif"; color:black}span.og{color:black}span.of{font-family: "Calibri","sans-serif";color:black}span.oe{font-size:8.0pt;font-family:"Verdana","sans-serif"; color:black}table.oy{border-collapse:collapse}tr.ob{height:.05pt} td.od{width:15.4pt;border:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}td.oc{width:421.5pt;border:solid black 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}td.oa{width:15.4pt;border:solid black 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}td.nz{width:166.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}td.nx{width:244.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}span.ny{font-size:8.0pt;font-family:"Verdana","sans-serif"}td.nw{width:421.5pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:.05pt}td.nv{width:138.0pt;border:solid black 1.0pt; padding:0cm .5pt 0cm .5pt}td.nu{width:38.8pt;border:solid black 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.nt{width:36.45pt;border:solid black 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt} td.ns{width:138.0pt;border:solid black 1.0pt; border-top:none;padding:0cm .5pt 0cm .5pt}td.np{width:38.8pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.oz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: right}span.nr{font-size:8.0pt;font-family:"Verdana","sans-serif";color:black}td.no{width:36.45pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.nm{width:48.35pt;border:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.nl{width:48.35pt;border:solid black 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}span.nk{font-size:8.0pt;font-family: "Verdana","sans-serif"}td.nj{width:41.6pt;border:solid black 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ni{width:41.6pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.pa{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.nh{font-family:"Calibri","sans-serif"; color:#0D0D0D}table.pb{width:517.4pt;margin-left:-12.75pt;border-collapse:collapse}td.ne{width:220.25pt;padding:0cm 5.4pt 0cm 5.4pt}p.pc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 7.1pt}td.nd{width:275.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.pd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";margin-left:7.1pt}span.nc{font-family: "Calibri","sans-serif"}p.pe{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}span.pf{color:black} span.pg{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif";color:black}span.ph{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"}span.pi{font-family:"Times New Roman","serif";font-family: "Calibri","sans-serif"; font-weight: bold} /**/
RNS Number : 8033Q
Advanced Oncotherapy PLC
22 February 2019
 

 

22 February 2019

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Grant of Options and 2018 SAYE Option Plan

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that its Remuneration Committee has approved the grant of share options (the "Options") over a total of 4,000,000 new ordinary shares of 25 pence each ("Ordinary Shares").

 

Of the Options, 545,000 have been granted to Dr Michael Sinclair (Executive Chairman), 1,400,000 to Nicolas Serandour (Chief Executive Officer), 215,000 to Professor Stephen Myers (Non-Executive Director of Advanced Oncotherapy and Executive Chairman of ADAM) and the remaining 1,840,000 to members of key management, including a PDMR.

 

The Options have been granted at an exercise price of 100 pence per share (implying a 141% premium over the closing share price on 20 February 2019). The options have a five-year term, expiring on 20 February 2024. This Option grant is consistent with the Remuneration Committee's policy to align the interests of key personnel and shareholders through appropriate incentive schemes, including the award of shares and share options. It follows recent achievements, including the recent ISO:13485 certification, the significant progress on the LIGHT system which generates a beam with an energy level capable of treating superficial tumours and the £10 million funding round announced on 21 December 2018.

 

Separately, pursuant to the Company's 2018 SAYE Option Plan and further to the announcement released on 21 December 2018, the Board has granted options over a total of 1,449,342 new Ordinary Shares (the "SAYE Options"). A total of 66 employees elected to participate in the 2018 SAYE Option Plan, including one employee who is classified as a PDMR.   

 

The SAYE Options have been granted at a price of 40 pence per share which is equivalent to the price of the £10 million funding round announced in December 2018. The SAYE Options have a savings contract start date of 1 March 2019 and are exercisable between 1 March 2022 and 31 August 2022.

 

Following the grant of the Options and the SAYE Options, the Company has options outstanding over 10,616,011 new Ordinary Shares, which represents approximately 5.46 per cent. of the Company's issued ordinary share capital.

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Sinclair (Director)

 

Nicolas Serandour (Director)

 

Steve Myers (Director)

 

Ed Lee (PDMR)

 

Bérengère Pons-Chabord (PDMR)

 

2

Reason for the notification

a)

Position/status

See 1 a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

 

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

b)

Nature of the transaction

Grant of options over new ordinary shares

c)

Price(s) and volume(s)

PDMR

 Price(s)

Volume(s)

Michael Sinclair (Director)

 

Nicolas Serandour (Director)

 

Steve Myers (Director)

 

Ed Lee (PDMR)

 

Bérengère Pons-Chabord (PDMR)

 

100p

 

100p

 

100p

 

100p

 

100p

 

545,000

 

1,400,000

 

215,000

 

215,000

 

140,000

 

d)

Aggregated information

- Aggregated volume

- Price

 Price(s)

Volume(s)

100p

2,515,000

e)

Date of the transaction

21 February 2019

f)

Place of the transaction

outside of a trading venue - grant of options

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bérengère Pons-Chabord

 

2

Reason for the notification

a)

Position/status

PDMRs

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

 

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

b)

Nature of the transaction

Grant of SAYE options over new ordinary shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

40p

 

45,000

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

21 February 2019

f)

Place of the transaction

outside of a trading venue - grant of SAYE options

 

For further information, please contact:

 

Advanced Oncotherapy Plc

Tel: +44 (0) 20 3617 8728

Dr. Michael Sinclair, Executive Chairman

www.avoplc.com

Nicolas Serandour, CEO




Allenby Capital Limited  (Nominated Adviser & Joint Broker)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Liz Kirchner / Nicholas Chambers




Stifel Nicolaus Europe (Joint Broker)

Tel: +44 (0) 20 7710 7600

Jonathan Senior




Walbrook PR (Financial PR & IR)

Paul McManus / Anna Dunphy

Tel: +44 (0) 20 7933 8780 [email protected]

Mob: +44 (0) 7980 541 893

Mob: +44 (0) 7876 741 001



About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDBGDDLGDBGCB

Quick facts: Advanced Oncotherapy PLC

Price: £0.40

Market: LSE
Market Cap: £92.09 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

RNS

Second Price Monitoring Extn

2 weeks, 1 day ago

Price Monitoring Extension

2 weeks, 1 day ago

Result of AGM

3 weeks, 6 days ago

Harley Street update

4 weeks, 2 days ago

Final Results

on 28/6/19